JNJ Johnson & Johnson
- 146.140
- -0.680-0.46%
- 146.140
- 0.0000.00%
Johnson & Johnson News
J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade
Investors in Johnson & Johnson (NYSE:JNJ) Have Unfortunately Lost 8.0% Over the Last Year
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both better or worse than that. Unfortunately the Johnson & Johnson (NYSE:JNJ) shar
Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment
Johnson & Johnson's (JNJ) Janssen-Cilag International said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Rybrevan
Are You Looking for a High-Growth Dividend Stock?
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170.
Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
By Ben Glickman Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates. The stock was up 42% to $17.50 in after-hours trading, follo
Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinic
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline
Johnson and Johnson (JNJ) Elliott Wave Technical Analysis [Video]
JNJ Elliott Wave Analysis Trading Lounge Daily Chart.
14 Dividend Growth Stocks With Highest Growth Rates
Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., Novo Nordisk, Eli Lilly and Company, Biocon
Johnson & Johnson China Chairman Proposes Resignation
Song Weiqun, Chairman of Johnson & Johnson China and President of Johnson & Johnson Medical Technology China, has proposed his resignation from the company to seek external development opportunities. According to public information, Song Weiqun joined the headquarters of Johnson & Johnson in the US in 2003 and has held leadership positions in the US, Australia, and New Zealand. In 2006, Song Weiqun returned to China to serve as the head of Johnson & Johnson Medical Technology's China Division; in 2015, he was promoted to the president of Johnson & Johnson Healthcare China; since 2018, he has also served as the chairman of Johnson & Johnson China. Johnson & Johnson insiders confirmed that Song Weiqun has confirmed that he will leave his job.
Johnson & Johnson (JNJ.US) & Legendary Biotech's CAR-T Therapy Receives EU Approval Again
Legendary Biotech announced that the European Commission (EC) has approved cilta-cel (cilta-cel, trade name Carvykti) for the treatment of adult patients with recurrent and refractory multiple myeloma. These patients have received at least first-line treatment (including a proteasome inhibitor and an immunomodulator), progressed in the last treatment and became resistant to lenalidomide. Sidakiolenol is a CAR-T therapy targeting B-cell maturation antigen (BCMA). In 2017/12, Johnson & Johnson (Johnson & Johnson)'s Johnson & Johnson Innovation System
Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)
Johnson & Johnson (NYSE:JNJ) will participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and
WHO No Longer Planning Safety Alert on Kenvue Cough Syrup: Report
10 Best Performing Biotech ETFs in 2024
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
EC Approved Carvykti For Treatment Of Relapsed/Refractory Multiple Myeloma
EC Approved Carvykti For Treatment Of Relapsed/Refractory Multiple Myeloma
Analysis
Price Target
No Data
